The Comparative Safety of Multiple Alternative Agents in Refractory Chronic Urticaria Patients

Sharon Seth, David A. Khan

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background Patients who have failed traditional treatment of chronic urticaria may require trials of alternative medications. Safety profiles, continuous laboratory monitoring, and physician comfort are often barriers to treatment. Objectives To evaluate the safety of alternative agents used in chronic urticaria. Methods A retrospective chart review of electronic medical records from a single-center allergy and immunology clinic in a major academic hospital was conducted. One hundred twenty-six charts of patients with chronic urticaria treated with alternative agents were reviewed. Results Adverse effects were reported in 39 of 73 (53%) patients on dapsone, 19 of 47 (40%) patients on sulfasalazine, 15 of 36 (42%) patients on tacrolimus, 7 of 45 (16%) patients on hydroxychloroquine, 9 of 27 (33%) patients on mycophenolate, 6 of 8 (75%) patients on cyclosporine, and 3 of 24 (4%) patients on omalizumab. Most of these adverse effects were mild, did not require discontinuation of the medication, and resolved after stopping the medication or decreasing the dose. Conclusions The use of alternative agents for the treatment of chronic urticaria angioedema is generally safe when proper laboratory and clinical monitoring is observed.

Original languageEnglish (US)
Pages (from-to)165-170.e2
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Urticaria
Safety
Hydroxychloroquine
Angioedema
Dapsone
Sulfasalazine
Electronic Health Records
Tacrolimus
Allergy and Immunology
Cyclosporine
Physicians
Therapeutics

Keywords

  • Alternative agents
  • Angioedema
  • Chronic urticaria
  • Dapsone
  • Hydroxychloroquine
  • Mycophenolate
  • Sulfasalazine
  • Tacrolimus

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

The Comparative Safety of Multiple Alternative Agents in Refractory Chronic Urticaria Patients. / Seth, Sharon; Khan, David A.

In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 5, No. 1, 01.01.2017, p. 165-170.e2.

Research output: Contribution to journalArticle

@article{53c87351d3704e0cbe53283694c438dc,
title = "The Comparative Safety of Multiple Alternative Agents in Refractory Chronic Urticaria Patients",
abstract = "Background Patients who have failed traditional treatment of chronic urticaria may require trials of alternative medications. Safety profiles, continuous laboratory monitoring, and physician comfort are often barriers to treatment. Objectives To evaluate the safety of alternative agents used in chronic urticaria. Methods A retrospective chart review of electronic medical records from a single-center allergy and immunology clinic in a major academic hospital was conducted. One hundred twenty-six charts of patients with chronic urticaria treated with alternative agents were reviewed. Results Adverse effects were reported in 39 of 73 (53{\%}) patients on dapsone, 19 of 47 (40{\%}) patients on sulfasalazine, 15 of 36 (42{\%}) patients on tacrolimus, 7 of 45 (16{\%}) patients on hydroxychloroquine, 9 of 27 (33{\%}) patients on mycophenolate, 6 of 8 (75{\%}) patients on cyclosporine, and 3 of 24 (4{\%}) patients on omalizumab. Most of these adverse effects were mild, did not require discontinuation of the medication, and resolved after stopping the medication or decreasing the dose. Conclusions The use of alternative agents for the treatment of chronic urticaria angioedema is generally safe when proper laboratory and clinical monitoring is observed.",
keywords = "Alternative agents, Angioedema, Chronic urticaria, Dapsone, Hydroxychloroquine, Mycophenolate, Sulfasalazine, Tacrolimus",
author = "Sharon Seth and Khan, {David A.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.jaip.2016.08.010",
language = "English (US)",
volume = "5",
pages = "165--170.e2",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - The Comparative Safety of Multiple Alternative Agents in Refractory Chronic Urticaria Patients

AU - Seth, Sharon

AU - Khan, David A.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background Patients who have failed traditional treatment of chronic urticaria may require trials of alternative medications. Safety profiles, continuous laboratory monitoring, and physician comfort are often barriers to treatment. Objectives To evaluate the safety of alternative agents used in chronic urticaria. Methods A retrospective chart review of electronic medical records from a single-center allergy and immunology clinic in a major academic hospital was conducted. One hundred twenty-six charts of patients with chronic urticaria treated with alternative agents were reviewed. Results Adverse effects were reported in 39 of 73 (53%) patients on dapsone, 19 of 47 (40%) patients on sulfasalazine, 15 of 36 (42%) patients on tacrolimus, 7 of 45 (16%) patients on hydroxychloroquine, 9 of 27 (33%) patients on mycophenolate, 6 of 8 (75%) patients on cyclosporine, and 3 of 24 (4%) patients on omalizumab. Most of these adverse effects were mild, did not require discontinuation of the medication, and resolved after stopping the medication or decreasing the dose. Conclusions The use of alternative agents for the treatment of chronic urticaria angioedema is generally safe when proper laboratory and clinical monitoring is observed.

AB - Background Patients who have failed traditional treatment of chronic urticaria may require trials of alternative medications. Safety profiles, continuous laboratory monitoring, and physician comfort are often barriers to treatment. Objectives To evaluate the safety of alternative agents used in chronic urticaria. Methods A retrospective chart review of electronic medical records from a single-center allergy and immunology clinic in a major academic hospital was conducted. One hundred twenty-six charts of patients with chronic urticaria treated with alternative agents were reviewed. Results Adverse effects were reported in 39 of 73 (53%) patients on dapsone, 19 of 47 (40%) patients on sulfasalazine, 15 of 36 (42%) patients on tacrolimus, 7 of 45 (16%) patients on hydroxychloroquine, 9 of 27 (33%) patients on mycophenolate, 6 of 8 (75%) patients on cyclosporine, and 3 of 24 (4%) patients on omalizumab. Most of these adverse effects were mild, did not require discontinuation of the medication, and resolved after stopping the medication or decreasing the dose. Conclusions The use of alternative agents for the treatment of chronic urticaria angioedema is generally safe when proper laboratory and clinical monitoring is observed.

KW - Alternative agents

KW - Angioedema

KW - Chronic urticaria

KW - Dapsone

KW - Hydroxychloroquine

KW - Mycophenolate

KW - Sulfasalazine

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=85008931497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008931497&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2016.08.010

DO - 10.1016/j.jaip.2016.08.010

M3 - Article

C2 - 27746265

AN - SCOPUS:85008931497

VL - 5

SP - 165-170.e2

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 1

ER -